Similarly, combination of CpG-oligo-deoxy-nucleotides, a known TLR9 agonist with recombinant ribosomal antigen L3 or L5 from L. major, improved the protection in two different murine models against homologous challenge infection (51). This evidence concerns the gene TLR9 and infection.